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OpinionGlossary
BDDCS: the Biopharmaceutics Drug Disposition Classification System, a
2  2 matrix that can be used to classify drugs into four main classes
depending on whether their solubility and/or extent of metabolism is ‘high’ or
‘low’; see [54].
KNIME: the Konstanz Information Miner (http://www.knime.org), a freely
available workflow environment for creating and running cheminformatics
and related workflows.For drug transport across (i.e., through) an intact biolog-
ical membrane, two main routes are possible: drugs may
cross (i) through the phospholipid bilayer portion of the
membrane, and/or (ii) via proteinaceous pores or trans-
porters. Perhaps surprisingly, there is in fact no direct
scientific evidence that the first of these takes place at
any significant rate because, in the experiments per-
formed to date, it has neither been varied as an indepen-
dent variable nor measured directly as a dependent
variable. Using a standard hypothetico-deductive frame-
work, I assess the intellectual and observable conse-
quences of assuming that, for drugs, phospholipid
bilayer diffusion is negligible – ‘PBIN’ – (i.e., may be
neglected, relative to transporter-mediated transmem-
brane fluxes). Predictions and postdictions of the PBIN
hypothesis are not refuted by available experimental
evidence.
Introduction
It is easy in science (and other fields) to take the ‘textbook’ or
‘standard’ view of a system or a process as a given, without
necessarily bothering to look into the actual experimental
evidence (if any) on which it might have been based. How-
ever, the history of science is full of examples in which a
theory or scientific viewpoint, once widely believed, was
supplanted by one that had better explanatory and predic-
tive power (i.e., of both existing and novel data) [1,2], albeit
often in the face of considerable rearguard action [3]. Some-
times this change in thinking was driven by the acquisition
of new evidence, but in some cases the main driver was
simply the reinterpretation of existing evidence – which
newer ideas must also necessarily explain.
This widespread acceptance of a particular view seems
to have come to pass in the field of cellular drug uptake,
where it is commonly believed that (leaving aside endocy-
tosis) most drugs can and do enter intact cells by passing0165-6147/
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physiologically based pharmacokinetic modelling.fully through whatever unhindered phospholipid bilayer
portions might exist, and – because biomembranes have
lipophilic interiors – at a rate that correlates (in some
fashion) with log D (see Glossary) or log P. I note, of course,
that correlations of two dependent variables show nothing,
except that they exist in the systems stated (while one may
be causal of the other, both might instead be effects of a
separate cause, or indeed entirely unrelated to each other
mechanistically). However, I know of no paper in which
phospholipid bilayer transport in intact biological cells has
ever been varied as an independent variable (and without
changing any relevant transporter-mediated uptake), nor
of any in which the actual passage of a drug diffusing
through the bilayer has ever been measured directly. It
therefore follows that the concrete, data-driven evidence
that we have that this takes place in vivo is, in fact,
precisely zero.
What has of course been done many times is that the
transfer of drugs across biological membranes has been
measured, and it has been assumed or stated that this
occurred via the bilayer. Obviously, assuming or stating
something as a mechanism when it has not actually been
measured directly can be rather hazardous, and indeed
does not count as experimental evidence for it at all. I
contrast the situation with experiments in which the ac-
tivity of genetically encoded protein transporters has been
varied independently (Figure 1).log D: the logarithm of the distribution coefficient, D. D is the ratio of the sum of
the concentrations of all forms of a compound (ionised plus non-ionised) in
each of two phases, typically 1-octanol and an aqueous buffer, whose pH must
be specified.
log P: the logarithm of the partition coefficient, P. P is a measure of the
hydrophobicity of a molecule; log P is the logarithm (base 10) of the ratio of the
concentration of a solute molecule in an organic solvent, usually 1-octanol, to
that of the non-ionised form of the same molecule in water.
Trends in Pharmacological Sciences, January 2015, Vol. 36, No. 1 15
Cytotoxic drug D –
entry eﬀected by transporter
Relavely high
[D] in cell.
Cell dies
Relavely low
or no D in cell.
Cell survives
Transporter
absent
Knockout of transporter
geneD
D
(A)
(B) (ii)
? (i)
D D
(iii)
D
TRENDS in Pharmacological Sciences 
Figure 1. Varying the mechanistic basis for drug uptake as an independent
variable causes predictable and measurable consequences. (A) This is
straightforwardly done for proteinaceous transporters, for instance by knocking
out the relevant genes, as illustrated for the case of a cytotoxic drug whose entry to
the cell is via a transporter coloured in blue. Other types of transporters (in green)
exist but are not used by the drug. Precisely these types of experiments have been
carried out for antimetabolites (e.g., [15]) and candidate anticancer drugs [22],
leading to straightforward and accurate inferences about the role of such
transporters in the uptake of the target drug(s). The uptake (and effectiveness) of
many other drugs has also been found to covary with the expression levels of
particular transporters (e.g., gemcitabine and ENT1 [46]). (B) By simply observing
the extracellular disappearance or intracellular uptake of a drug, one may seek to
infer that the transport of the externally added drug entering a cell occurs (i) via its
transport through the bilayer. Obviously, other interpretations of the mechanisms
of this drug transport are possible, however, such as transport through the blue (ii)
or green (iii) transporters (or both). Thus, no logically correct inference is possible
if neither bilayer diffusion nor the presence or activity of relevant transporters are
varied in known ways, nor measured directly. We are aware of no experiments in
which phospholipid bilayer transport has been varied independently in this way,
and under circumstances where any changes in competing transporter-mediated
uptake have also been monitored (figures not drawn to scale).
SLCO1B1
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Figure 2. A typical biomembrane, drawn approximately to scale. The illustration
uses common protein:phospholipid mass ratios, and shows a typical drug
(atorvastatin), also drawn to scale. Phospholipids are in brown, proteins in other
colours. The question arises as to whether any of the drug passes through those
phospholipid bilayer regions that remain unaffected by the presence of the
proteins. According to this Opinion, it is much easier to account for many types of
observations if one recognises that in fact the overwhelming bulk of
transmembrane drug transport occurs via proteinaceous pores and transporters
(that are involved in intermediary metabolism) and not through phospholipid
bilayers. Abbreviation: SLCO1B1, solute carrier organic anion transporter family,
member 1B1.
Opinion Trends in Pharmacological Sciences January 2015, Vol. 36, No. 1In a separate strand of activity, researchers have stud-
ied the transport of drugs across protein-free lipid (or
other hydrophobic) bilayers or membrane structures. On
the assumption that cells also contain similar phospholip-
id bilayers, and that these are not modified materially by
the presence of (what is, by mass, usually considerably
more) protein (Figure 2), they have been tempted to ex-
trapolate such in vitro findings to biological membranes in
vivo. This again lacks real logic because the properties of
biological membranes do differ in many ways from those of
these artificial ones (not least by the presence of aqua-
porins [4]).
Few studies have systematically sought to understand
how drug uptake and cellular lipid composition may co-
vary; however, if one believes (as I do not) that most (or a
significant part) of the uptake flux of drugs in intact cell
membranes occurs via phospholipid bilayers, such lipid
variation is not to be invoked as a major mechanism of
variable uptake anyway because, for a significant number
of drugs, the majority of the difference in (‘background’)
rates between, for example, MDCK and Caco-2 cells does
not vary more than twofold [5].16Thus, starting in 2008 [6], my colleagues and I have
been developing the idea that the phospholipid bilayer
portion of intact biological membranes is not in fact
naturally significantly permeable to drugs and common
xenobiotics because evolution simply selected against
that (and note of course that biomembranes are osmoti-
cally active). Arguably it is precisely the ‘laminated’
hydrophilic–hydrophobic–hydrophilic structure of phos-
pholipid bilayers that stops real, undamaged biomem-
branes from being leaky to small molecules (in either
direction). Leaving aside endocytosis, paracellular trans-
port, and so on, then, and concentrating on cases where a
drug genuinely traverses a cellular (or indeed intracellu-
lar) membrane, how drugs do cross membranes is to be
seen as being via the many proteinaceous transporters
(e.g., [7,8]) (Figure 2) encoded by the relevant genome.
Many of those for small molecules are recorded in the
metabolic networks reconstructed and curated, for exam-
ple for yeast [9] and humans [10,11]. Of course, these
transporters are taken to be there not specifically for the
benefits of pharmaceuticals companies but for the pur-
poses of intermediary metabolism. To this end we have
summarised the evidence for the dominance of transport-
er-mediated uptake in several review and experimental
articles [5,6,12–19].
However, such reviews are necessarily retrospective.
By contrast, if one starts (as a hypothesis [20,21]) by
accepting that the phospholipid bilayer diffusion of drugs
across intact biological membranes is negligible (PBIN),
a great many interesting and thus prospective conse-
quences follow, that I explore below. I shall point at some
of the relevant evidence, but readers will wish to judge
for themselves the extent to which the observations
(including their own) have yet been made or not, and
whether the PBIN view thus has useful predictive (or
postdictive) power. I group the consequences into three
classes; some consequences really relate to more than
one class.
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Consequences of a low or negligible natural
permeability to drugs of phospholipid bilayers in intact
biomembranes
Most tissues (lacking transporters) will not in fact take up
drugs in significant amounts unless suitable proteinaceous
transporters are present. A particularly clearcut example
has recently been provided by Superti-Furga and collea-
gues [22], who used a near-haploid human cell line [23,24]
in a very elegant manner to show that the candidate (and
rule-of-5-compliant) anticancer drug sepantronium bro-
mide (or YM155) simply does not enter mammalian cells
unless a particular transporter (SLC35F2: solute carrier
family 35, member F2) is present. There is neither a
detectable effluxer nor any significant background trans-
port (i.e., this demonstrates PBIN in a very clear way).
Indeed, it is worth stressing that if background (lipoidal
bilayer-dependent) rates of uptake were not negligible this
type of experiment [15] could not and would not work.
Because the expression profiles of transporters vary
strongly between different tissues in an organism (e.g.,
http://www.proteinatlas.org), there will be an extreme het-
erogeneity of uptake of specific drugs into the cells and
tissues of that organism (as in [25]). This might be ob-
served, for instance, by mass spectral imaging, or by other
spectroscopic techniques that can effect spatially distinct
chemical imaging, and has been (e.g., [26–28]).
Such heterogeneity can lead to distributions of drugs in
tissues that differ widely, despite the same gross pharma-
cokinetics/pharmacodynamics; a tissue in which two thirds
of the cells take up no drug and one third take up three
times as much still takes up the same total amount of drug,
but may display both lack of efficacy (in the two-thirds) and
toxicity (in the one-third) [19]; these two causes account for
the bulk of present-day attrition in drug-discovery pro-
grams [29,30]. One cannot properly use ensemble (average)
measurements to disguise functional cellular heterogene-
ity [31,32].
If phospholipid bilayer diffusion is normally negligible,
there will be tissues (largely lacking in transporters that
may be expressed elsewhere) which, despite the relative
functional similarity of their phospholipids, are very poor
at taking up drugs: the blood–brain [33], blood–testis [34],
and blood–retina [35] barriers exhibit these properties. Of
course, drug efflux transporters can also contribute to this
type of phenomenon [36], but poor uptake transport follows
directly from PBIN.
Thus, PBIN accounts easily for all types of variation in
the uptake of drugs as cellular circumstances are varied
because, if something like a cell or tissue type is changed,
so too are the expression levels (or activities) of the rele-
vant transporters in those cells of the organism (and the
heterogeneity is enormous, and can be measured; e.g.,
http://www.proteinatlas.org). By contrast, there is little
obvious tissue-specificity of the permeability properties
of phospholipid bilayers, nor therefore any major means
by which those who believe it to be important can expect it
to vary so much between different cells or tissues in an
organism. In a similar vein, PBIN provides a natural and
simple explanation for the variation of uptake of the same
drug between individuals whose transporter activities mayvary as a result of single-nucleotide polymorphisms or
other genetic differences (pharmacogenomics) [37]. PBIN
also provides a natural and simple explanation for the
variation (which can be huge [38,39]) of uptake of the same
drug between different species (of organism). Furthermore,
PBIN provides a natural and simple explanation for any
variation of uptake of the same drug as an organism
changes its physiology, for example diurnally [40], via
nutritional changes, or exercising, in disease, or as it ages,
etc.
A straightforward prediction is that molecular dynam-
ics (MD) simulations of ‘real’ biomembranes, set up with
natural protein:phospholipid ratios of 2:1 or 3:1, will show
that drugs do not cross them at significant rates via the
phospholipid bilayer portion (but may do so overwhelm-
ingly via the relevant transporters if they are present in
the same membrane simulation). Such MD simulations of
transporters embedded in realistic membranes are indeed
beginning to appear (e.g., [41–43]).
Consequences of the fact that individual drugs must and
do use specific and identifiable transporters
Proteinaceous transporters will be discovered for all xeno-
biotics that cross biomembranes; a survey of TransPortal
[44] or DrugBank [45] indicates that at least one trans-
porter is already known for most drugs. Furthermore,
there will be clear relations (sensu lato) between the extent
of drug uptake and the expression levels of particular
transporters in different cells or tissues; the fluorinated
anti- (pancreatic) cancer nucleoside gemcitabine provides
one example (e.g., [46,47]).
Removing or decreasing the activity of a particular
transporter by genetic or other means will change in a
predictable way the extent of uptake of drugs that are its
substrates [15,22]. If removing all relevant transporter
activity leads to negligible uptake then one may clearly
infer that phospholipid bilayer diffusion is negligible. Sim-
ilarly, increasing the activity of a particular transporter by
genetic or other means will change in a predictable way the
extent of uptake of drugs that are its substrates [48]. This
and the previous paragraph probably represent the most
important strategies by which one may usefully assess the
relevance of specific transporters in the cellular uptake of a
named drug.
Finally, drugs (and metabolites and nutrients) that
share the same transporter will compete with each other
for it [49,50], and the covariation of their uptake between
tissues will tend in part to follow the covariation of trans-
porter expression.
Consequences of the fact that specific drugs hitchhike
on transporters that mainly have intermediary
metabolites as their natural substrates
Because the natural substrates of these transporters are
posited to be (and in many cases clearly are) intermediary
metabolites, the principle of molecular similarity implies
that successful (i.e., marketed) oral drugs, that necessarily
cross biomembranes, will bear structural similarities to
at least one metabolite (Figure 3), as has been shown
[12,18], and this should be useful in drug design. The
structural similarities between marketed drugs and17
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Figure 3. The metabolite-likeness of drugs. A comparison (based on [18]) of the structural similarities of marketed drugs and the majority of the metabolites of the human
metabolic network reconstruction Recon2 [10]. Drugs that are also metabolites were removed from the list of drugs. Using the MACCS encoding [61], the similarity of each
substance is compared via a KNIME workflow [62] using the Tanimoto similarity coefficient [63,64], whose values are encoded according to the colours indicated. Drugs and
metabolites are clustered using an agglomerative clustering algorithm. A full description is given elsewhere [18], but for 90% of all marketed drugs there is at least one
metabolite with a Tanimoto (structural) similarity using the MACCS encoding of 0.5 or greater. This could be used as a powerful filter during drug-discovery programmes.
Abbreviations: KNIME, Konstanz Information Miner; MACCS, Molecular Access System.
Opinion Trends in Pharmacological Sciences January 2015, Vol. 36, No. 1human metabolites will also apply for the subset of natural
molecules that undergo transmembrane transport
[12]. From a cheminformatics point of view [51], the better
descriptors relating drugs to metabolites will be molecular
and substructural descriptors rather than bulk biophysi-
cal ones such as log P or ‘total polar surface area’; these
need to be assessed using suitable hold-out sets [52].
If bilayer diffusion is both important and is claimed to be
correlated with log P or log D, then log P or log D should be
predictive of cellular uptake. By contrast, because of the
molecular specificity of at least some transporters, PBIN
predicts that there will be only a very weak or limited
correlation between (i) the ability of drugs to cross mem-
branes or (as a surrogate) to be metabolised, and (ii) their
bulk log D or log P values; examples (often using tabulated
rather than plotted data) include [53,54]. Figure 4 shows
data replotted from the tables in [54], which would lead one18to suppose that the cellular permeability of drugs is largely
independent of the distribution coefficient (log D) of those
drugs between buffer (pH 7.4) and octan-1-ol.
Although many enzymes are highly promiscuous [14],
and transporters are enzymes, there will be identifiable
quantitative structure–activity relationships (QSARs) for
each transporter that – when learned – will have high
predictive power for untested drugs (independently of
biophysical indicators such as log D or log P). Such QSAR
and pharmacophore models are beginning to appear [55].
Non-discriminating experiments
I have concentrated on experiments and data that seem to
pertain to the predictions of PBIN. However, I am mindful
that there is a danger of researchers proposing experiments
that, however superficially attractive, are not in fact dis-
criminatory of the two main mechanisms under discussion
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Figure 4. The cellular permeability of drugs versus log D. There is no obvious
relationship between the cellular permeability of various drugs (assessed via the
percentage unchanged in the urine, given that the metabolism of drugs requires
their cellular uptake, and a low value therefore reflects a high permeability) and the
measured distribution coefficient at pH 7.4. All data are from [54] (similar but more
extensive data show the same when the abscissa is the log P as calculated and
displayed in the same table from [54], not shown). The BDDCS class is encoded by
the colour as marked, and the aqueous solubility by the size of the symbol.
Opinion Trends in Pharmacological Sciences January 2015, Vol. 36, No. 1here. Thus, varying something like temperature to see its
effects on drug uptake, especially if one is not measuring all
of the activities of the transporter, will be uninterpretable.
Similarly, varying lipid composition without assessing the
effects of doing that on transporter activities themselves will
also not be discriminatory because a substantial literature
shows that phospholipids can have profound effects on the
activities of membrane proteins (see e.g., [56,57]), as can
nutrient molecules (e.g., [58]). Finally, debates around bi-
layer diffusion tend to obsess about topics such as satur-
ability, promiscuity, stereoselectivity, and the effects of
(usually non-existent) inhibitors; the first three in particular
are completely non-discriminatory, in contrast to the main
class of experiment that we have stressed is worth doing,Box 1. Outstanding questions
Question
 How can we measure bilayer-mediated transport or diffusion in real
biomembranes directly?
 Can we modify phospholipids in a manner that changes their
interactions with other lipids, but not those with protein transpor-
ters, and that thereby affects drug uptake?
 Will we be able to do molecular dynamics (MD) simulations for long
enough to observe full transbilayer diffusion at rates comparable to
those of transporter-mediated fluxes?
 A motivation for addressing drug–metabolite likeness came from a
recognition of the importance of drug transporters. While metabo-
lite likeness is a now demonstrable property of most marketed
drugs, are drugs closer in structure to the subset of metabolites that
are transported across membranes in vivo?
 Can the recognition of the role of transporters in cellular drug
uptake help in understanding some of the origins of unexpected lack
of efficacy and/or toxicity, and thereby help to decrease the
appalling late-stage attrition rates still prevailing?
 Can comparative genomics help in understanding species differ-
ences in drug transport(ers)?which is simply to vary the expression and activities of the
transporter proteins themselves and to assess the predicted
or predictable consequences on drug uptake.
Concluding remarks
Sometimes it is useful to take a step back and, instead of
starting with observable data and seeking the hypothesis
that best explains them, start with a hypothesis (that did of
course originate from data [20]) and assess what might be
the predictions or consequences that follow if that hypoth-
esis were to be true. This hypothesis then might be (or
indeed might already have been) subjected to experimental
assessment to see if the observable data might serve to
falsify it.
A theory that explains more observations and has pre-
dictive power is normally to be preferred over one that
performs less well by those metrics. One example, that I
have highlighted before in this context [5,6,14,19], relates
to the change in recognition that general anaesthetics,
whose potency is typically well correlated with lipophilicity
up to a cut-off (that is connected with their solubility),
actually cause anaesthesia not by interacting with the
phospholipid bilayer but by binding to hydrophobic pockets
on target proteins that are in fact the ‘cause’ (mechanism)
of the anaesthesia [59]. In particular, the well-known and
strong relationship between the potency of various general
anaesthetics and log P, long assumed to be due to mem-
brane partitioning, can be reproduced with the soluble
enzyme luciferase [60].
The hypothesis-led approach is the one I have taken
here, and the many publications analysed in our various
papers on this topic (e.g., [5,6,12–17,19]) provide data
and evidence that, perhaps surprisingly, or even shock-
ingly, thus far fail to falsify the hypothesis that, for the
transport of pharmaceutical drugs across intact biologi-
cal membranes, phospholipid bilayer diffusion is negligi-
ble. Many opportunities for novel approaches exist
(Box 1), however, and I look forward to further tests of
these consequences.Possible approaches
 Possibly spectroscopic methods such as NMR or ESR would give
signals that differ as drugs pass through the different parts of a
phospholipid bilayer versus being transported via a transporter.
 There may be a role for incorporating phospholipid analogues with
‘click chemistry’, or other suitably reactive groups, that do not
themselves make membranes non-specifically leaky.
 Computer power has historically increased 1000-fold every 6 years
(though their power consumption has not). Specialised hardware
implementations will help. Nevertheless, clever shortcuts will be
necessary. MD methods provide an in silico approach that may be
very useful if definitive ‘wet’ experiments prove intractable.
 Fairly standard cheminformatics analyses should be able to address
these types of question.
 This probably requires a metabolic network model that incorporates
the transporters and their expression profiles, and that also under-
stands the QSARs for each main transporter to assess distributions
at a sub-tissue level.
 This would require a sequence-based approach coupled to knowledge
of major differences in drug distributions between different species.
19
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